Feature | March 31, 2014

Terumo to Purchase Arterial Remodeling Technologies’ Bioresorbable Stent Technology

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART Security Holders will retain full ownership of the ART bioresorbable scaffold technology for all other indications. Terumo Corp. will make staged R&D investments in ART, and ART has granted an exclusive option to Terumo Corp. to purchase ART at any time prior to the initiation of clinical trials.

ART’s advanced bioresorbable scaffold is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months, which is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodeling.

ART wishes to thank its investors: Bpifrance, Idinvest Partners, Turenne Capital Partners, Matignon Investissement & Gestion, Vesale Partners and Amundi Asset Management.

ART also wishes to thank three esteemed institutions for their invaluable support: the Cleveland Clinic; the French national research institute, CNRS, Montpellier, France; and Descartes University, Paris.

ART’s bioresborbable stent is not approved for investigational use or sale in the United States.

For more information: www.art-stent.com, www.terumomedical.com

Related Content

Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Abbott, Absorb bioresorbable stent, dissolving, UAB, University of Alabama at Birmingham, first in state
News | Stents Bioresorbable| July 26, 2016
On July 20, Massoud Leesar, M.D., of University of Alabama at Birmingham Hospital implanted a patient with Absorb, the...
SJM, OCT, Optical coherence tomography, Bioresorbable stent, BVS

An optical coherence tomography (OCT) image of an Absorb bioresorbable stent. The stent struts are clear, allowing light to pass through, and in some cases magnifying the light that passes through under each strut. Image courtesy of St. Jude Medical.

Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of inter
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
Abbott, Absorb bioresorbable stent, University Hospitals Case Medical Center, first Midwest implant
News | Stents Bioresorbable| July 11, 2016
University Hospitals Case Medical Center, Cleveland, is among the first in the country – and the first in Ohio — to...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, dissolving stent

The Abbott Absorb is the first bioresorbable stent to be cleared for use in the United States. 

Technology | Stents Bioresorbable| July 05, 2016 | Dave Fornell
July 5, 2016 — The U.S.
News | Stents Bioresorbable| June 06, 2016
Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel Aptitude 120-...
congenital heart, pulmonary artery stenting, JACC study
News | Congenital Heart| May 31, 2016
In a recent study, the use of a stent to repair pulmonary artery stenosis in children and adults with congenital heart...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable| May 17, 2016
Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016.
Overlay Init